all report title image
  • To Be Published : Jan 2023
  • Code : CMI4988
  • Industry : Pharmaceutical
  • Pages : N/A
  • Formats :

Complex regional pain syndrome (CRPS) is a neuropathic pain disorder defined by the presence of distinct clinical features, including allodynia, hyperalgesia, sudomotor, and vasomotor abnormalities, ccurring as a result of tissue trauma, injury, surgery, sprain, etc. CRPS is a condition of chronic pain that affects the legs, arms, feet, and hands, which occurs after an injury.

There are two subtypes of CRPS-type I, formerly known as reflex sympathetic dystrophy and type II, formerly known as causalgia. Type I occurs in the absence of nerve injury, while type II occurs in the case of known nerve injury.

Global Complex Regional Pain Syndrome Market: Dynamics

The rising number of patients suffering from complex regional pain syndrome (CRPS), chronic pain, and failed back syndrome are the key factors driving the growth of the complex regional pain syndrome market. For instance, in 2017, there were 219,317 prevalent cases of CRPS in the U.S.

Moreover, the rising number of initiatives undertaken by non-profit organizations, increasing R&D funding by private and public organizations, and various government initiatives to increase the awareness about the syndrome are expected to drive the market growth during the forecast period. For instance, U.S. Pain Foundation, a non-profit organization, is dedicated to serving those who live with conditions that cause chronic pain. The mission of the U.S. Pain Foundation is to empower, educate, and connect people struggling with painful chronic conditions.

Furthermore, increasing R&D activities and FDA approvals of upcoming drugs are expected to drive the market growth during the forecast period. For instance, in September 2021, FDA granted orphan drug status to Soin Therapeutics, an Ohio based pharmaceutical company, for low dose Naltrexone (LDN) to treat Complex Regional Pain Syndrome (CRPS).

Global Complex Regional Pain Syndrome Market: Restraints

The major factors that hinder the growth of complex regional pain syndrome market include lack of in-depth knowledge of CRPS, scarcity of medical and behavioral pain management experts, and lack of effective treatment options.

Global Complex Regional Pain Syndrome Market: Regional Insights

Among regions, North America is expected to hold the largest market share in the global complex regional pain syndrome market over the forecast period. The market growth in these regions is mainly due to increasing awareness of disease remittance therapies among patients, the rising prevalence of CRPS, and high public and private healthcare spending. Moreover, easy access to quality healthcare, a strong clinical pipeline, and approval of novel drugs are expected to drive the market growth in North America.

Furthermore, Asia Pacific is likely to become the fastest growing market throughout the forecast period. Increasing healthcare spending is expected to drive the market growth in this region. Moreover, favorable regulatory policies for drug approval is expected to boost growth of the market in this region over the forecast period.

Global Complex Regional Pain Syndrome Market: Competitive landscape

The key players operating in the global complex regional pain syndrome market include Boston Scientific Corporation, GlaxoSmithKline plc., Johnson & Johnson, Viatris, Sanofi S.A, and Medtronic Plc.

Global Complex Regional Pain Syndrome Market: Taxonomy

By Disease Type:

  • CRPS I
  • CRPS II
  • CRPS - NOS

By Drug Type:

  • T-121
  • NTRX-07
  • Neridronic Acid
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo